Brief: Genocea Presents Promising Long-Term Results From Gen-009 Neoantigen Vaccine Phase 1 Trial At Asco 2021
04/06/2021 15:34
June 4 (Reuters) - Genocea Biosciences Inc GNCA.O :
* GENOCEA PRESENTS PROMISING LONG-TERM RESULTS FROM GEN-009
NEOANTIGEN VACCINE PHASE 1 TRIAL AT ASCO 2021
* GENOCEA BIOSCIENCES INC - TWO OF SEVEN CPI-REFRACTORY
PATIENTS
EXPERIENCED STABLE DISEASE FOR UP TO 10 MONTHS AFTER INITIAL
GEN-009 VACCINATION
Source text for Eikon: ID:nGNX75qRTM
Further company coverage: GNCA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genocea Biosciences
See all newsBluebird, Chimerix, Clovis have under 6 months of cash left - Truist
Genocea Biosciences plunges as it winds down operations
Brief: Genocea Announces Wind Down Of Operations And Delisting From Nasdaq
Genocea Biosciences Inc reports results for the quarter ended in March - Earnings Summary
U.S. STOCKS ON THE MOVE-Oppenheimer Holdings, IES Holdings Inc, Avantor Inc